Cargando…

Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker

Genetic abnormalities have been conventionally considered as hallmarks of cancer. However, recent studies have demonstrated that epigenetic mechanisms are also implicated in the insurgence and development of cancer. Patterns of the epigenetic component include DNA methylation and histone modificatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zagni, Chiara, Citarella, Andrea, Oussama, Mahjoub, Rescifina, Antonio, Maugeri, Alessandro, Navarra, Michele, Scala, Angela, Piperno, Anna, Micale, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412695/ https://www.ncbi.nlm.nih.gov/pubmed/30795625 http://dx.doi.org/10.3390/ijms20040945

Ejemplares similares

Assessment of Therapeutic Bio-Activity of Cinnamoyl Sulfonamide Hydroxamate in Squamous Cell Carcinoma
por: Cherian, Eapen, et al.
Publicado: (2023)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

Pseudo-Dipeptide Bearing α,α-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses
por: Citarella, Andrea, et al.
Publicado: (2021)

SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors
por: Citarella, Andrea, et al.
Publicado: (2021)

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities
por: Yang, Feifei, et al.
Publicado: (2019)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
por: Frühauf, Anton, et al.
Publicado: (2021)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
por: Ptacek, Jakub, et al.
Publicado: (2023)

Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities
por: Chu, Jung-Chun, et al.
Publicado: (2023)

Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives
por: Citarella, Andrea, et al.
Publicado: (2023)

Cinnamoylthiourea
por: Hassan, Ibrahim N., et al.
Publicado: (2010)

Synthesis and HDAC inhibitory activity of pyrimidine-based hydroxamic acids
por: Jakubkiene, Virginija, et al.
Publicado: (2022)

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway
por: Shi, Xuan-Yan, et al.
Publicado: (2017)

Hydroxamic acid-modified peptide microarrays for profiling isozyme-selective interactions and inhibition of histone deacetylases
por: Moreno-Yruela, Carlos, et al.
Publicado: (2021)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
por: Ghazy, Ehab, et al.
Publicado: (2022)

Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines
por: Sixto-López, Yudibeth, et al.
Publicado: (2020)

Molecular docking and ADMET analysis of hydroxamic acids as HDAC2 inhibitors
por: Alsawalha, Murad, et al.
Publicado: (2019)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)
por: Friedrich, Annabelle, et al.
Publicado: (2020)

A Novel Hydroxamic Acid-Based Curcumin Derivative as Potent Histone Deacetylase Inhibitor for the Treatment of Glioblastoma
por: Wang, Hao, et al.
Publicado: (2021)

1,3-Diphenylureido hydroxamate as a promising scaffold for generation of potent antimalarial histone deacetylase inhibitors
por: Tavares, Maurício T., et al.
Publicado: (2023)

Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual‐Targeting HDAC Inhibitors and HDAC Degraders (PROTACs)
por: Sinatra, Laura, et al.
Publicado: (2020)

The potential for histone deacetylase (HDAC) inhibitors as cestocidal drugs
por: Vaca, Hugo Rolando, et al.
Publicado: (2021)

Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast
por: Seo, Jinwon, et al.
Publicado: (2014)

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor
por: Richon, V M
Publicado: (2006)

A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors
por: Goracci, Laura, et al.
Publicado: (2016)

Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry Applications
por: Citarella, Andrea, et al.
Publicado: (2021)

Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins
por: Dai, Yan, et al.
Publicado: (2008)

Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer
por: Xu, Xiaoxin S, et al.
Publicado: (2011)

The Role of Dietary Histone Deacetylases (HDACs) Inhibitors in Health and Disease
por: Bassett, Shalome A., et al.
Publicado: (2014)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Histone Deacetylase Inhibitors, Intrinsic and Extrinsic Apoptotic Pathways, and Epigenetic Alterations of Histone Deacetylases (HDACs) in Hepatocellular Carcinoma
por: Sanaei, Masumeh, et al.
Publicado: (2021)

CD4(+) T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2
por: Boucheron, Nicole, et al.
Publicado: (2014)

Induction of histone deacetylases (HDACs) in human abdominal aortic aneurysm: therapeutic potential of HDAC inhibitors
por: Galán, María, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_oilc4o30opvk1esb54dntq9de7